Celltrion Healthcare to sell ‘Herzuma’ in 7 European countries

Published: 2018-06-25 16:23:30

Updated: 2018-06-25 16:24:33

Celltrion Healthcare is expanding the number of countries to sell ‘Herzuma(generic name: trastuzumab),’ an antibody biosimilar for the treatment of breast cancer and stomach cancer.

Celltrion Healthcare launched ‘Herzuma’ in Spain, Portugal, Netherlands, Austria and Island and started to sell the product in total 7 European countries including England and Germany last month, the company announ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.